JY
BTAI icon

Jeff Yass’s BioXcel Therapeutics BTAI Stock Holding History

Jeff Yass’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-781
Closed -$7.63K – 12233
2024
Q3 		$7.63K Sell
781
-7,482
-91% -$101K ﹤0.01% 11737
2024
Q2 		$169K Buy
8,263
+407
+5% +$13.6K ﹤0.01% 10570
2024
Q1 		$354K Sell
7,856
-4,063
-34% -$194K ﹤0.01% 9310
2023
Q4 		$563K Buy
11,919
+5,000
+72% +$278K ﹤0.01% 8367
2023
Q3 		$280K Sell
6,919
-10,731
-61% -$1.08M ﹤0.01% 9501
2023
Q2 		$1.88M Buy
17,650
+15,650
+783% +$5.21M ﹤0.01% 5277
2023
Q1 		$597K Sell
2,000
-200
-9% -$85.4K ﹤0.01% 8126
2022
Q4 		$756K Sell
2,200
-888
-29% -$215K ﹤0.01% 6808
2022
Q3 		$584K Sell
3,088
-1,818
-37% -$422K ﹤0.01% 8066
2022
Q2 		$1.04M Buy
4,906
+2,087
+74% +$439K ﹤0.01% 6461
2022
Q1 		$943K Sell
2,819
-1,112
-28% -$322K ﹤0.01% 7280
2021
Q4 		$1.28M Sell
3,931
-4,144
-51% -$1.78M ﹤0.01% 6615
2021
Q3 		$3.92M Sell
8,075
-1,550
-16% -$682K ﹤0.01% 4402
2021
Q2 		$4.47M Buy
9,625
+5,225
+119% +$2.85M ﹤0.01% 4237
2021
Q1 		$3.04M Sell
4,400
-5,631
-56% -$4.53M ﹤0.01% 4920
2020
Q4 		$7.42M Buy
10,031
+6,593
+192% +$5.14M ﹤0.01% 2865
2020
Q3 		$2.38M Sell
3,438
-6,450
-65% -$4.84M ﹤0.01% 4285
2020
Q2 		$8.39M Buy
9,888
+5,475
+124% +$3.57M ﹤0.01% 2352
2020
Q1 		$1.58M Buy
+4,413
New +$1.59M ﹤0.01% 4403

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's BTAI Position: Q2 2026 in Review

Jeff Yass opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 17,200 shares worth $24.3K. The stake represents ﹤0.01% of the portfolio and ranks #13005 among its holdings. This is a return to the name: Jeff Yass previously reported a position in BTAI as recently as Q4 2024.

Jeff Yass first reported a position in BTAI in Q2 2020 and has held it in 19 quarters since. The position peaked at $9.99M in Q3 2020. 46 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Jeff Yass held 17,200 shares of BioXcel Therapeutics worth $24.3K as of Q2 2026.
  • BioXcel Therapeutics was a new Jeff Yass position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #13005 holding.
  • Jeff Yass first reported a position in BioXcel Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • Jeff Yass's BioXcel Therapeutics position peaked at $9.99M in Q3 2020.
  • 46 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.